Market Cap 383.88M
Revenue (ttm) 0.00
Net Income (ttm) -84.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,506,700
Avg Vol 2,021,136
Day's Range N/A - N/A
Shares Out 47.69M
Stochastic %K 40%
Beta 3.33
Analysts Hold
Price Target $8.00

Company Profile

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 254 4445
Address:
100 Forge Road, Suite 700 Watertown, Watertown, United States
FreeBeerTomorrow
FreeBeerTomorrow Aug. 5 at 7:42 AM
$VIGL Vigil Neuroscience (VIGL) stock is halted because of a pending merger with Sanofi. The merger was approved by shareholders and the stock was halted in anticipation of the deal closing. The final day of trading for VIGL was August 4, 2025, and the stock will be suspended effective August 6, 2025.
0 · Reply
Mergerbrief
Mergerbrief Aug. 4 at 12:07 PM
$VIGL / $SNY - Shareholder Vote $VIGL MergerBrief.com For Full Schedule
0 · Reply
theoptionsplug
theoptionsplug Jul. 21 at 5:25 AM
The most overbought stocks according to their 14-day RSI: Monogram Technologies $MGRM, Cogent Biosciences Inc $COGT, and Vigil Neuroscience $VIGL The most oversold stocks according to their 14-day RSI: Intapp $INTA and NextNRG $NXXT
0 · Reply
GOLDENSAFEBETS
GOLDENSAFEBETS Jul. 19 at 2:47 PM
$VIGL 🐂🧃💎
0 · Reply
Norbert90
Norbert90 Jul. 9 at 3:22 PM
$VIGL No more free CVRs.
1 · Reply
BioTechHealthX
BioTechHealthX Jul. 6 at 5:30 PM
$VIGL Learn why Sanofi’s $600M acquisition of Vigil Neuroscience could signal a shift in Alzheimer’s treatment. VIGL may still have room to run. https://biotechhealthx.com/biotech-news/vigil-neuroscience-vigl-the-tiny-biotech-sanofi-just-bet-600m-on/
1 · Reply
junglezoo
junglezoo Jul. 6 at 3:41 PM
0 · Reply
Norbert90
Norbert90 Jul. 2 at 1:23 PM
$VIGL Third and final quarter. Any updates on timeline for the deal closing?
1 · Reply
Joe_088
Joe_088 Jul. 2 at 1:21 PM
$DWTX $VIGL $WINT 3 stock was 💎💎💎
0 · Reply
Ridiculous78
Ridiculous78 Jun. 26 at 10:24 PM
$VIGL Made some good money here. You will be missed 👍🏼
0 · Reply
Latest News on VIGL
Sanofi to Buy Vigil Neuroscience for About $470 Million

May 21, 2025, 7:59 PM EDT - 2 months ago

Sanofi to Buy Vigil Neuroscience for About $470 Million

SNY


Sanofi to acquire Vigil Neuroscience in $470 million deal

May 21, 2025, 7:29 PM EDT - 2 months ago

Sanofi to acquire Vigil Neuroscience in $470 million deal

SNY


Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

Mar 12, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days


Vigil Neuroscience: Interesting Early Data, Wait For Phase 2

Sep 18, 2023, 2:38 PM EDT - 2 years ago

Vigil Neuroscience: Interesting Early Data, Wait For Phase 2


FreeBeerTomorrow
FreeBeerTomorrow Aug. 5 at 7:42 AM
$VIGL Vigil Neuroscience (VIGL) stock is halted because of a pending merger with Sanofi. The merger was approved by shareholders and the stock was halted in anticipation of the deal closing. The final day of trading for VIGL was August 4, 2025, and the stock will be suspended effective August 6, 2025.
0 · Reply
Mergerbrief
Mergerbrief Aug. 4 at 12:07 PM
$VIGL / $SNY - Shareholder Vote $VIGL MergerBrief.com For Full Schedule
0 · Reply
theoptionsplug
theoptionsplug Jul. 21 at 5:25 AM
The most overbought stocks according to their 14-day RSI: Monogram Technologies $MGRM, Cogent Biosciences Inc $COGT, and Vigil Neuroscience $VIGL The most oversold stocks according to their 14-day RSI: Intapp $INTA and NextNRG $NXXT
0 · Reply
GOLDENSAFEBETS
GOLDENSAFEBETS Jul. 19 at 2:47 PM
$VIGL 🐂🧃💎
0 · Reply
Norbert90
Norbert90 Jul. 9 at 3:22 PM
$VIGL No more free CVRs.
1 · Reply
BioTechHealthX
BioTechHealthX Jul. 6 at 5:30 PM
$VIGL Learn why Sanofi’s $600M acquisition of Vigil Neuroscience could signal a shift in Alzheimer’s treatment. VIGL may still have room to run. https://biotechhealthx.com/biotech-news/vigil-neuroscience-vigl-the-tiny-biotech-sanofi-just-bet-600m-on/
1 · Reply
junglezoo
junglezoo Jul. 6 at 3:41 PM
0 · Reply
Norbert90
Norbert90 Jul. 2 at 1:23 PM
$VIGL Third and final quarter. Any updates on timeline for the deal closing?
1 · Reply
Joe_088
Joe_088 Jul. 2 at 1:21 PM
$DWTX $VIGL $WINT 3 stock was 💎💎💎
0 · Reply
Ridiculous78
Ridiculous78 Jun. 26 at 10:24 PM
$VIGL Made some good money here. You will be missed 👍🏼
0 · Reply
Stocks4thought
Stocks4thought Jun. 26 at 11:10 AM
$TCRX Its another $SGMT OR $VIGL - they drive them deep and then algo-s build tremendous wealth. Saw it with $SLNO cost basis $3.42. GO Figure or Go f the traders.
0 · Reply
BinaryLogic
BinaryLogic Jun. 26 at 2:38 AM
0 · Reply
GreylockSec
GreylockSec Jun. 23 at 11:08 PM
$TPST ....A nice little buyout from this past May from Sanofi that sort of went under the radar, yet still brings a bit of fresh hopium into the small-cap biotech world.... ...Sanofi bought only one of two therapies developed by $VIGL Vigil, being its lead, stage-2-ready, Alzheimer's candidate (a TREM-2 protein that shows up on immune cells in the brain, and still remains a mostly uncharted target) for a whopping $470 million in cash (or $8/share) and another $2 worth of CVRs should the therapy progress...A big payout for a Stage-1 (potential) therapy. ....Small, Stage-1 experimental therapy buyouts like this one by big-pharma help to shape the appearance of a rising biotech comeback with such forward-thinking investments already this year. Thank God Brady knows his science.
0 · Reply
Stocks4thought
Stocks4thought Jun. 23 at 1:49 PM
$ANIX $SGMT $VIGL it works https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/
0 · Reply
Quantumup
Quantumup Jun. 23 at 12:03 PM
Canaccord Genuity reiterated $VTYX Buy-$14 after Ventyx reported positive results from the Phase lla open-label study for VTX3232 in early Parkinson's disease (PD). $VIGL - $SNY Canaccord Genuity said in its note; "The trial's positive results demonstrated effective inhibition of NLRP3 and suppression of downstream biomarkers. Results from the trial support once-daily dosing. Ventyx plans to initiate a Phase II dose-ranging study for the drug in patients with Parkinson's. We are encouraged by the reported results from the Phase lla trial, and we believe the study results support a potential indication of VTX3232 in additional neurodegenerative diseases. We remain bullish on shares of $VTYX and reiterate our $14 12-month PT."
0 · Reply
LifeisaMeme
LifeisaMeme Jun. 19 at 5:35 PM
$VTYX $RGLS $VIGL What kind of engineering did you study
0 · Reply
BinaryLogic
BinaryLogic Jun. 19 at 3:55 PM
$VTYX $RGLS $VIGL [Again]
0 · Reply
jacksparo
jacksparo Jun. 16 at 11:52 PM
$VERV Big pay day comes for whom the ones hold this one from my email few weeks ago!! Big move AH with buy out news! The second buy out in less than three weeks from Jack emails! Remember $VIGL And now VERV!
1 · Reply
Stocks4thought
Stocks4thought Jun. 16 at 8:03 PM
$ANIX Just like $VIGL $SGMT they rise- I believe stocks are so manipulated to the downside- to enable [positioning for huge gains- follow suit- https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/
1 · Reply
BinaryLogic
BinaryLogic Jun. 14 at 11:59 PM
$VTYX Look at $RGLS and $VIGL, then come to $VTYX and you will see that some investor(s) are consistently and continuously building here, methodically, taking the SP off of Overbought conditions then continuing to climb. Look at the product pipeline here: multiple phase-2/3 candidates across Crohn's, ulcerative colitis, Parkinson's and peridcarditis. Now-look at the financial statements. This Company has more than doubled over the last month and it is still valued under BV! Excellent acquisition target with 3-5X additional upside (IMO). https://ventyxbio.com/pipeline/
1 · Reply
Quantumup
Quantumup Jun. 12 at 7:15 PM
Piper Sandler, on June 9, reiterated $VTYX OW-$21 and said "we remain bullish on $VTYX's robust NLRP3 portfolio and believe these key readouts are de-risked given its straightforward MoA validated by approved IL-1ß agents." $VIGL - $SNY Piper Sandler additionally said in its note to investors:
0 · Reply
NancyPelosi____insider
NancyPelosi____insider Jun. 12 at 5:35 PM
0 · Reply